Call Me Free
Home ›› Products ›› API ›› Axitinib API
Previous Product Next Product
Axitinib API

Axitinib API

Axitinib API, a second-generation tyrosine kinase inhibitor, selectively targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), impeding angiogenesis, tumor proliferation, and metastasis. Renowned for its potency, Axitinib surpasses first-generation VEGFR inhibitors by 50-450 times, showcasing its efficacy in combating cancer progression. As an indazole derivative, Axitinib API stands as a promising therapeutic agent in oncology, offering targeted treatment options for various malignancies. Its precise mechanism of action and enhanced potency underscore its pivotal role in cancer therapy, providing hope and improved outcomes for patients battling cancer.

Inquiry Now

Manufacturing Unit-I

Block/Survey No. 497, Mauhuvej, nr. Fairdeal Textile Park, Kosamba, Gujarat 394125, India